The use of rhIL‐3 for mobilization of peripheral blood The International Journal of Cell Cloning in previously treated patients with lymphoid malignancies

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

In a phase I trial, we evaluated the ability of rhIL‐3 to mobilize peripheral blood The International Journal of Cell Cloning in patients with lymphoid malignancies. Six patients with Hodgkin's disease (HD) and two patients with non‐Hodgkin's lymphoma (NHL) who were to receive high‐dose therapy and peripheral stem cell transplantation, received rhIL‐3 stimulation at the first 3 dose levels ‐ 125 mcg/M2 (N=3), 250 mcg/M2 (N=3), and 500 mcg/M2 (N=2). The patients ranged in age from 19–60 years (median 33) and had received a median of 1 chemotherapy regimen prior to the peripheral stem cell collection. The patients received rhIL‐3 subcutaneously for a total of 14 days. They underwent stem cell apheresis prior to the first rhIL‐3 dose as a base line and subsequently on days 5,8,11,13 and 14 of the rhIL‐3 administration. The median baseline CFU‐GM was 0.02 × 104/kg, 0.04 × 104/kg, and 0.01 × 104/kg for patients at the 125 mcg/M2, 250 mcg/M2, and 500 mcg/M2 doses respectively. This rose to a peak median value of 0.25 × 104/kg, 0.15 × 104/kg, and 0.02 × 104/kg for each of respective dose levels. The median BFU‐E and CFU‐Meg values also rose with rhIL‐3 administration; however, not consistently. These preliminary results document the effectiveness of peripheral stem cell recruitment by rhIL‐3 for use with high‐dose therapy and peripheral stem cell transplantation.

Original languageEnglish (US)
Pages (from-to)62-64
Number of pages3
JournalThe International Journal of Cell Cloning
Volume10
Issue number1 S
DOIs
StatePublished - Jan 1992

Keywords

  • Cytokines
  • Interleukin‐3
  • Lymphoid malignancies

ASJC Scopus subject areas

  • Cell Biology

Fingerprint Dive into the research topics of 'The use of rhIL‐3 for mobilization of peripheral blood The International Journal of Cell Cloning in previously treated patients with lymphoid malignancies'. Together they form a unique fingerprint.

  • Cite this